Grouping mutations into their respective complexes and comparison across cancer types showed that most types where ≥ 5% of the tumors showed activation of the NRF2 pathway also displayed SWI/SNF mutation frequencies from 10%-50% (Fig 1A). This evidence concerns the gene NFE2L2 and cancer.